DeBogy Molecular


Biotechnology company developing surface-modification technologies that permanently alter material surfaces to provide contact-active antimicrobial activity. Focus areas include engineering treated surfaces for medical devices and a range of industrial and consumer materials, with preclinical data supporting efficacy and biocompatibility.

Industries

biotechnology
health-care
medical

Nr. of Employees

small (1-50)

DeBogy Molecular

5350 Beckley Road, Battle Creek, MI 49015


Patents

Methods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers

US-12290072-B2

View Details

Methods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers

US-11019819-B2

View Details

Methods of use and processes for preparing alcoholic solutions of polyvinylpyridine polymers

US-10743539-B2

View Details

Ready-to-use storable methanolic solution of a biocompatible and biocidal polyvinylpyridine polymer

US-10238110-B2

View Details

Products

Proprietary surface-modification platform

A molecular platform designed to modify material surfaces to exert contact-active antimicrobial effects across a range of substrates.


Services

Surface-treatment services and technology for imparting contact-active antimicrobial properties to a range of substrates for medical, textile and industrial applications.

A platform of proprietary molecules intended to be immobilized on material surfaces to provide permanent biocidal activity without soluble antibiotics or toxic additives.

Coordination and commissioning of external CROs for animal-model testing of surface-treated devices.

Expertise Areas

  • Surface modification and functionalization
  • Antimicrobial materials development
  • Preclinical in vivo testing for implant-associated infection
  • Biocompatibility assessment
  • Show More (3)

Key Technologies

  • Surface chemical functionalization
  • Immobilized antimicrobial molecular agents
  • Electrostatic microbial membrane disruption
  • Preclinical in vivo biofilm models
  • Show More (2)

News & Updates

Preclinical in vivo study reporting substantial reductions in bacterial biofilm and surrounding tissue bacterial load on treated implants versus control; study used a high MRSA inoculum in a mouse model.

In a mouse implant model, treated titanium implants showed a 99.97% reduction in bacterial biofilm vs untreated control at 7 days; surrounding tissue bacterial load reduced by 99.8% with improved local tissue histology and reported biocompatibility.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.